U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07651319) titled 'Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease' on June 02.
Brief Summary: Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited. Growing evidence suggests that inflammation in the brain and the body plays a key role in the onset and progression of AD. In particular, immune cells called regulatory T cells (Tregs), which normally help control inflammation, are impaired in AD individuals. This leads to increased activity of harmful immune pathways that worsen brain injury. Interleukin-2 (IL-2) is a drug tha...